Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes
Year: 2019
Type: article
Abstract: Pediatric HIV infection remains a large global health concern despite the widespread use of antiretroviral therapy (ART). Thus, global elimination of pediatric HIV infections will require the development of novel immune-based approaches, and understanding infant immunity to HIV is critical to guide the rational design of these intervention strategies. Despite their immunological immaturity, HIV-infected children develop broadly neutralizing antibodies (bnAbs) more frequently and earlier than adults do. Furthermore, T-follicular helper (Tfh) cells have been associated with bnAb development in HIV-infected children and adults. To further our understanding of age-related differences in the development of HIV-specific immunity, we evaluated the generation of virus-specific humoral immune responses in infant (n=6) and adult (n=12) rhesus macaques (RMs) infected with a transmitted/founder (T/F) simian-human immunodeficiency virus (SHIV.C.CH505). The plasma HIV envelope-specific IgG antibody kinetics were similar in SHIV-infected infant and adult RMs, with no significant differences in the magnitude or breadth of these responses. Interestingly, autologous tier 2 virus neutralization responses also developed with similar frequency and kinetics in infant and adult RMs, despite infants exhibiting significantly higher Tfh and germinal center B cell frequencies compared to adults. Our results indicate that the humoral immune response to SHIV infection develops with similar kinetics among infant and adult RMs, suggesting that the early life immune system is equipped to respond to HIV-1 and promote the production of neutralizing HIV antibodies. Importance There is a lack of understanding on how the maturation of the infant immune system influences immunity to HIV infection, or how these responses differ from those of adults. Improving our knowledge of infant HIV immunity will help guide antiviral intervention strategies that take advantage of the unique infant immune environment to successfully elicit protective immune responses. We utilized a rhesus macaque model of SHIV infection as a tool to distinguish the differences in HIV humoral immunity in infants versus adults. Here, we demonstrate that the kinetics and quality of the infant humoral immune response to HIV are highly comparable to that of adults during the early phase of infection, despite distinct differences in their Tfh responses, indicating that slightly different mechanisms may drive infant and adult humoral immunity.
Source: Journal of Virology
DOI: 10.1128/jvi.00168-19
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Funders: University of Pennsylvania, Frederick National Laboratory for Cancer Research, National Institutes of Health, Center for AIDS Research, University of Washington, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research, California National Primate Research Center
Awards: G103941647, G1214792496, G1533825516, G1852790566, G226574744, G2493518942, BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy, Transmission-blocking potential of novel HIV Env-specific mucosal antibodies, Early Life Vaccination to Prevent HIV acquisition during Adolescence, Innate antiviral factors in breast milk and the oral HIV-1 reservoir, Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, Viral Oncology Training Grant, Combined Hepatitis B and HIV-1 envelope vaccination to augment T cell help via linked recognition of unrelated antigens, G654751394, G6714156533, G674907753, G7124282841, bNAb induction by antigenically diverse V1V2 lineage specific SHIVs and SOSIPs, G9000000688, G9000057924, G9000263633, G9000266210, SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine design, California National Primate Research Center, The University of North Carolina Center for AIDS Research, Center for AIDS Research, Cancer Center Support Grant
OpenAlex ID: W2953341569
